Pulse Biosciences

3957 Point Eden Way
Hayward
CA
94545
United States

Tel: 510-906-4600

Website: https://www.pulsebiosciences.com/

About Pulse Biosciences

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that improves and extends the lives of patients. The Company utilizes its patented groundbreaking Nano-Pulse Stimulation™ (NPS™) technology to treat a variety of applications for which an optimal solution remains unfulfilled. NPS is a proprietary technology that delivers nano-second pulses of high amplitude electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue. The cell-specific effects of NPS technology have been validated in a series of ongoing clinical trials. In addition, early pre-clinical evidence suggests that the NPS technology holds a promising future in immuno-oncology by demonstrating an ability to induce immunogenic cell death. The CellFX System, the first planned commercial product to harness the distinctive advantages of NPS technology, is preparing to launch in 2019 as a multi-application platform designed to address a broad range of dermatologic conditions. As part of the customer experience, the Company is offering an utilization-based revenue model and easy-access customer portal offering a suite of services. CellFX procedures offer customer value across an expanding spectrum of clinical applications. The initial commercial use will be the clearance of common skin lesions, including sebaceous hyperplasia (SH) and seborrheic keratosis (SK) – two prevalent and difficult-to-treat benign skin conditions that share high demand among patients and practitioners for improved and durable aesthetic outcomes that lead to greater overall satisfaction. For more information about Pulse Biosciences, proprietary NPS technology, or CellFX, please visit us at PulseBiosciences.com.

Stock Exchange: NASDAQ

Stock Symbol: PLSE

59 articles with Pulse Biosciences

Pulse Biosciences Grants Equity Incentive Awards to New Employees - June 17, 2019

6/18/2019

Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 17,750 shares of Pulse Biosciences common stock to three recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on June 17, 2019.
Pulse Biosciences Grants Equity Incentive Awards to New Employees - May 15, 2019

5/15/2019

Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 110,500 shares of Pulse Biosciences common stock to five new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on May 15, 2019.
Pulse Biosciences Quarterly Investor Conference Call - April 30, 2019

4/30/2019

Pulse Biosciences, Inc. reported recent corporate developments and financial results for the quarter ended March 31, 2019.
Pulse Biosciences to Report First Quarter 2019 Operational Highlights and Financial Results

4/18/2019

Pulse Biosciences, Inc., a novel medical therapy company bringing to market its proprietary CellFX™ System announced that the Company will report first quarter 2019 operational highlights and financial results on Tuesday, April 30, 2019.
Pulse Biosciences Grants Equity Incentive Awards to New Employees - April 15, 2019

4/15/2019

Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 28,000 shares of Pulse Biosciences common stock to three new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on April 15, 2019.
Pulse Biosciences Announces Presentations at the 2019 American Society for Laser Medicine and Surgery Annual Conference

3/26/2019

Pulse Biosciences, Inc. announced that key findings from its clinical programs using Nano-Pulse Stimulation™ technology will be presented at the American Society for Laser Medicine and Surgery’s Annual Conference being held March 27-31, 2019, in Denver, CO.
Pulse Biosciences Appoints Mitchell Levinson to Board of Directors

3/19/2019

In connection with his appointment to the board, Mr. Levinson will also serve as a member of the audit committee.
Pulse Biosciences Grants Equity Incentive Awards to New Employees - March 18, 2019

3/15/2019

Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 61,000 shares of Pulse Biosciences common stock to three new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on March 15, 2019.
Pulse Biosciences Announces Late Breaking Oral Presentation of Sebaceous Hyperplasia Study Results at the 2019 AAD Annual Meeting

3/1/2019

Pulse Biosciences, Inc. announced that clinical results from its recently completed Sebaceous Hyperplasia study will be presented at the American Academy of Dermatology Annual Meeting
Pulse Biosciences Submits 510(K) to U.S. FDA for CellFX™ System

2/28/2019

Pulse Biosciences, Inc., a novel medical therapy company bringing to market its proprietary CellFX™ System announced the Premarket Notification 510 submission to the U.S. Food and Drug Administration for its CellFX System.
Pulse Biosciences Grants Equity Incentive Awards to New Employees on February 15, 2019

2/15/2019

Pulse Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 37,250 shares of Pulse Biosciences common stock to eight new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on February 15, 2019.
Pulse Biosciences Quarterly Investor Conference Call - February 7, 2019

2/7/2019

First patient treated in the CellFX™ back acne clinical feasibility study
Pulse Biosciences to Report Fourth Quarter and Full Year 2018 Operational Highlights and Financial Results

1/29/2019

Pulse Biosciences, Inc. today announced that the Company will report fourth-quarter and full-year 2018 operational highlights and financial results on Thursday, February 7, 2019.
Pulse Biosciences Announces Two Appointments Focused on CellFX™ Commercialization: Promotion of Edward Ebbers and Addition of Robert Tyson

1/17/2019

− Ebbers named Executive Vice President and General Manager, Dermatology − Tyson named Vice President, Sales North America
Pulse Biosciences Grants Equity Incentive Awards to New Employees on January 15, 2019

1/15/2019

Pulse Biosciences, Inc. announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 23,750 shares of Pulse Biosciences common stock to three new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on January 15, 2019.
Pulse Biosciences Announces Positive Clinical Results of Its Nano-Pulse Stimulation™ Technology Platform to Treat Patients with Sebaceous Hyperplasia Lesions on the Face

1/7/2019

Multi-center study with leading researchers demonstrates significant efficacy with over 99.5% of Sebaceous Hyperplasia lesions treated with Nano-Pulse Stimulation™ technology rated as clear or mostly clear by investigators
Pulse Biosciences Grants Equity Incentive Awards to New Employees on December 17 2018

12/17/2018

Pulse Biosciences, Inc., announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 17,500 shares of Pulse Biosciences common stock to two new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on December 15, 2018.
Pulse Biosciences, Inc. Announces Closing of Its $45 Million Rights Offering

12/14/2018

Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, announced today that its rights offering has closed.
Pulse Biosciences, Inc. Announces Oversubscription, Pricing and Preliminary Results for Its $45 Million Rights Offering

12/7/2018

Pulse Biosciences, Inc. today announced the completion of its rights offering, which expired at 5:00 p.m. Eastern Time on December 6, 2018 (the “Expiration Date”).
Pulse Biosciences, Inc. Announces Commencement of Rights Offering of $45,000,000 of its Common Stock

11/19/2018

Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced that it has commenced its previously announced rights offering of $45,000,000 of its common stock.